BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3921384)

  • 1. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.
    Ferrari C; Rampini P; Paracchi A; Boghen M; Mailland F
    Eur J Clin Pharmacol; 1985; 27(6):707-11. PubMed ID: 3921384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions.
    Ferrari C; Romussi M; Benco R; Rampini P; Mailland F
    Acta Endocrinol (Copenh); 1983 May; 103(1):1-6. PubMed ID: 6407250
    [No Abstract]   [Full Text] [Related]  

  • 3. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ibopamine on serum prolactin and growth hormone levels in hyperprolactinemic and acromegalic subjects.
    Ferrari C; Barbieri C; Caldara R; Rampini P; Paracchi A; Boghen M; Rauhe WG
    Clin Pharmacol Ther; 1983 Jul; 34(1):74-8. PubMed ID: 6861440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The correlationship between basal prolactin levels and the suppressive effect of CB-154 or L-DOPA on GH release in acromegalic patients (author's transl)].
    Hara I; Kataoka K; Tomita A; Takanohashi M; Nakane T; Kuwayama A; Kageyama N
    Nihon Naibunpi Gakkai Zasshi; 1979 Jan; 55(1):16-24. PubMed ID: 581754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients.
    Verde G; Oppizzi G; Colussi G; Cremascoli G; Botalla L; Müller EE; Silvestrini F; Chiodini PG; Liuzzi A
    Clin Endocrinol (Oxf); 1976 Jul; 5(4):419-23. PubMed ID: 971548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone-releasing factor increases serum prolactin concentrations in normal subjects and in patients with pituitary adenomas.
    Serri O; Somma M; Rasio E; Brazeau P
    Clin Endocrinol (Oxf); 1989 Jan; 30(1):65-75. PubMed ID: 2505955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between the thyrotrophin-releasing hormone-induced growth hormone rise and dopaminergic drugs: studies in pathologic conditions of the animal and man.
    Müller EE; Salerno F; Cocchi D; Locatelli V; Panerai AE
    Clin Endocrinol (Oxf); 1979 Dec; 11(6):645-56. PubMed ID: 119594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a dopaminergic activity of methysergide in humans.
    Oppizzi G; Verde G; De Stefano L; Cozzi R; Botalla L; Liuzzi A; Chiodini PG
    Clin Endocrinol (Oxf); 1977 Oct; 7(4):267-72. PubMed ID: 923106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone and prolactin in tissue culture of pituitary adenoma.
    Demura R; Kubo O; Odagiri E; Nomura K; Yamaguchi H
    Endocrinol Jpn; 1977 Jun; 24(3):259-64. PubMed ID: 913336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
    Losa M; Schopohl J; König A; Müller OA; von Werder K
    J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man.
    Masturzo P; De Maria A; Murialdo G; Bonura ML; Zauli C; Polleri A
    J Clin Endocrinol Metab; 1985 Aug; 61(2):378-81. PubMed ID: 4008612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
    Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
    Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects.
    Camanni F; Massara F; Belforte L; Rosatello A; Molinatti GM
    J Clin Endocrinol Metab; 1977 Mar; 44(3):465-73. PubMed ID: 838847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients.
    Camanni F; Picotti GB; Massara F; Molinatti GM; Mantegazza P; Müller EE
    J Clin Endocrinol Metab; 1978 Sep; 47(3):647-52. PubMed ID: 263317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
    Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel features of tumors that secrete both growth hormone and prolactin in acromegaly.
    Nyquist P; Laws ER; Elliott E
    Neurosurgery; 1994 Aug; 35(2):179-83; discussion 183-4. PubMed ID: 7969823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary.
    Lawton NF; Evans AJ; Weller RO
    J Neurol Sci; 1981 Feb; 49(2):229-39. PubMed ID: 7217982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.